BRIEF—Eisai reveals presentations for ASCO 2023

Japanese drugmaker Eisai has outlined the research it plans to present at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO).

Perhaps most significantly, an oral presentation of overall survival (OS) results from the Phase III CLEAR will provide an insight into the use of Lenvima (lenvatinib) plus Keytruda (pembrolizumab), Merck & Co’s checkpoint blocker.

The trial compares the combo with sunitinib for the first-line treatment of people with advanced renal cell carcinoma.

Among other presentations will be a post-hoc analysis, presented as a poster, from the REFLECT trial of Lenvima monotherapy in first-line liver cancer.

Chief scientific officer Takashi Owa said: "The outlook for advanced renal cell carcinoma has evolved in recent years, and the final analysis from the pivotal CLEAR trial to be presented at ASCO represents another step forward for patients and an opportunity to provide their physicians with long-term data.”